Ballydel Technologies Inc.

Ballydel Technologies Inc. is a for-profit, small business manufacturer specializing in advanced materials science, defense research, and technology innovation. Based in Wilmington, Delaware with operations in Talleyville, the company develops specialized detection systems, sensing technologies, and advanced materials solutions for federal agencies. The firm is registered in SAM.gov and maintains an active federal contracting profile, leveraging expertise in materials science, aerospace applications, and innovative sensor technologies to deliver critical capabilities for defense and national security missions.

Through federal contract awards, Ballydel Technologies has demonstrated substantial expertise in chemical defense and sensing applications, primarily supported by the U.S. Army's Research, Development and Engineering Command (RDECOM). Most notably, the company received a $1.31 million Phase III Small Business Innovation Research (SBIR) contract awarded in September 2025 for design and development of a chemical warfare agent detection system—specifically a spray or foam applicator capable of marking blister chemical warfare agent contamination on surfaces for visual identification, with performance expected through September 2027. Prior to this, Ballydel completed Phase I and Phase II SBIR work on chemical warfare agent detection, including a $197,281.34 Phase I contract focused on developing a bifunctional fluorescent probe for detecting mustard gas and phosgene, and a $1.1 million Phase II SBIR modification contract. The company has also pursued advanced materials development through Small Business Technology Transfer (STTR) awards, including a $1.15 million Phase II STTR contract with RDECOM for developing phosphine sensing polymer composites integrated into optical fiber extrusion processes, and a $172,987.16 Phase I STTR contract for a low-cost, non-invasive phosphine sensor. Additionally, Ballydel received a $1.25 million Phase II STTR award from the Air Force Research Laboratory in July 2023 for scalable MXene synthesis for aerospace applications, building on earlier Phase I work valued at $149,997, and a $239,990 Phase I STTR contract from the U.S. Marine Corps under Topic 24.1-003. The company also completed a $124,930 NASA SBIR Phase I contract for research on joining carbon-carbon composites using field-assisted sintering technology. All contract awards have been designated as Total Small Business set-asides, reflecting the company's small business status and supporting its participation in critical research and development initiatives.

Through federal grant awards, Ballydel Technologies has focused on pharmaceutical supply chain security and product authentication technologies, leveraging support from the National Science Foundation (NSF). The company received a $951,394 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) awarded in June 2024 for developing serialized anti-counterfeit labeling technology for pharmaceutical and biological products. This Phase II effort aims to create a scalable manufacturing process for imprinting covert, encrypted patterns onto labels for individual vaccine vials, incorporating serialized codes to enable traceability and authentication throughout the supply chain, with completion targeted for May 2026. This award builds upon earlier NSF support through a $256,000 Project Grant awarded in May 2021 for tagging and authentication technology for vaccines, specifically addressing COVID-19 vaccine security challenges. Both grants emphasize the development of state-of-the-art, counterfeit-proof security technologies that enable manufacturers to tag, track, and authenticate vaccine products throughout the supply chain while demonstrating scalable production methodologies and handheld reader systems for product authentication at any point in the distribution network.